Adagio Medical Announces Pricing of up to $50 Million Private Placement of Securities
Summary
The private placement is expected to close during the week of October 13, 2025, subject to the satisfaction of customary closing conditions.Piper Sandler is acting as sole placement agent for the private placement.Lake Street is serving as financial advisor to the Company in the offering.The securities to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the Securities Act), or any state or other applicable jurisdictions securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions securities laws.This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS Cryoablation System, which is CE Marked and is currently under evaluation in the Companys FULCRUM-VT U.S. IDE Pivotal Study.This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning: the expected closing of the private placement; the receipt of additional gross proceeds if the accompanying Warrants are exercised in full; the Companys intended use of the proceeds from the private placement; and the Companys strategy, future operations, future financial position, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management and the potential for FDA approval of the Companys product candidates. Risks regarding Adagios business are described in detail in Adagios Securities and Exchange Commission (SEC) filings, including in its Annual Report on Form 10-K for the full-year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are available on the SECs website at www.sec.gov.